From the New York Times today, Celera Genomics is going to stop selling subscription access to its genomics databases, instead transferring the information to the public. According to the Times, their subscriptions have been steadily declining, and this is a good way to generate goodwill. In our laboratory, we've been splitting the difference between Celera and the public databases for some time already.
Data brevia, ars longa. It is very hard for a scientist to sit still, even having amassed a few more data points than the other fellow (although it never hurts). Data are like new cars, losing a chunk of their value as they drive off the lot. Celera is an extreme example of this value decay.